Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 7/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265568 | 0.88 | SOS1 (0.45) | JAK2JAK1TYK2JAK3SYK | |
| SCHEMBL14536378 | 0.85 | ROCK1 (0.46) | JAK2JAK1TYK2JAK3AXL | |
| SCHEMBL266257 | 0.83 | SYK (0.48) | JAK2JAK1TYK2JAK3AXL | |
| SCHEMBL270122 | 0.80 | AXL (0.46) | JAK2JAK1TYK2JAK3AXL | |
| SCHEMBL277891 | 0.79 | AXL (0.36) | JAK2JAK1TYK2JAK3AXL | |
| Hydrochloric Acid SCHEMBL266775 | 0.79 | AXL (0.46) | JAK2JAK1TYK2JAK3AXL | |
| SCHEMBL265022 | 0.75 | BRD4 (0.38) | JAK2JAK1TYK2JAK3AXL | |
| SCHEMBL265114 | 0.74 | KDR (0.40) | ROCK1DYRK1A | |
| SCHEMBL270515 | 0.74 | SYK (0.51) | JAK2JAK1JAK3AXLTYRO3 | |
| SCHEMBL264636 | 0.73 | SYK (0.65) | JAK2TYK2JAK3AXLBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | JAK2 1/4885JAK1 4/4885TYK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.